Antares Pharma Announces FDA Acceptance of New Drug Application for Quickshot® Testosterone
Feb 27, 2017 12:01 pm UTC| Business
EWING, N.J., Feb. 27, 2017 -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the New Drug Application (NDA) for QuickShot® Testosterone (QST), a drug-device combination product for the delivery of testosterone...
Antares Pharma Announces FDA Acceptance of New Drug Application for Quickshot® Testosterone
Feb 27, 2017 12:01 pm UTC| Business
EWING, N.J., Feb. 27, 2017 -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the New Drug Application (NDA) for QuickShot® Testosterone (QST), a drug-device combination product for the delivery of testosterone...
Feb 27, 2017 12:01 pm UTC| Business
PLYMOUTH MEETING, Pa., Feb. 27, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance and inducing neo-antigen-like T cell...
Feb 27, 2017 12:01 pm UTC| Business
PLYMOUTH MEETING, Pa., Feb. 27, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance and inducing neo-antigen-like T cell...
Feb 27, 2017 12:01 pm UTC| Business
DEVENS, Mass., Feb. 27, 2017 -- AMSC (NASDAQ:AMSC), a global energy solutions provider serving wind and power grid industry leaders, today announced that AMSC will partner with Black Veatch to perform a study to...
Feb 27, 2017 12:01 pm UTC| Business
DEVENS, Mass., Feb. 27, 2017 -- AMSC (NASDAQ:AMSC), a global energy solutions provider serving wind and power grid industry leaders, today announced that AMSC will partner with Black Veatch to perform a study to...
National General Holdings Corp. Reports Fourth Quarter 2016 Results
Feb 27, 2017 12:01 pm UTC| Business
NEW YORK, Feb. 27, 2017 -- National General Holdings Corp. (NASDAQ:NGHC) today reported fourth quarter 2016 net income of $30.9 million or $0.28 per diluted share, compared to $13.7million or $0.13 per diluted share in...